One common class of drugs alters how neurotransmitters are cleared from the synaptic cleft
Serotonin Selective Reuptake Inhibitors (SSRIs) are drugs that inhibit the function of the reuptake transporter found in synapses that release the neurotransmitter serotonin
Reuptake transporters are proteins that bind to neurotransmitters and remove them from the synaptic cleft
Some examples of SSRIs are Prozac and Zoloft, which both treat mood disorders
Drugs usually impact neurotransmitters in one of two ways: as an agonist or antagonist
An agonist is a drug that enhances the activity of a neurotransmitter
Agonist drugs often mimic the action of the endogenous neurotransmitter it binds to
Endogenous means naturally occurring
Competitive agonists compete for the same binding site with the endogenous neurotransmitter
For competitive agonists to be effective, they usually need to be more concentrated than the endogenous neurotransmitter
Noncompetitive agonists are also called allosteric modulators
Noncompetitive agonists can increase the activity of the neurotransmitter without blocking its binding site
Partial agonists compete for the same binding site, but have a smaller physiological effect on the postsynaptic receptor than the usual neurotransmitter
An antagonist drug decreases or even fully blocks the activity of the neurotransmitter
Antagonist drugs work to prevent the binding or the action of the endogenous neurotransmitter
Competitive antagonists block the binding site of a receptor
Noncompetitive antagonists bind at a different site than the endogenous neurotransmitter, which in turn changes the shape of the receptor to decrease the effect of the usual neurotransmitter
An allosteric site is a site on a protein that can be modified by a second molecule (Where noncompetitive antagonists go)
L-DOPA is an agonist that is used to treat Parkinson's disease
Parkinson's disease involves the death of dopamine-producing neurons in the basal ganglia
L-DOPA increases the amount of dopamine in the neurons of the brain